This article is more than 5 years old. Information may no longer be current.

RenalytixAI signs agreement for lab services

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

RenalytixAI, a developer of artificial intelligence-enabled diagnostics for kidney disease, has completed a joint venture partnership agreement with AKESOgen, a commercial laboratory facility and provider of clinical trial precision medicine services. The combined company will be called RENX AI Labs, LLC.

“AKESOgen brings a state-of-the-art CLIA-certified and CAP-accredited laboratory facility that enables RenalytixAI to immediately scale operations to support additional business partnerships,” RenalytixAl said in a press release. “RENX AI Labs significantly expands the operational capacity available to RenalytixAI and enables RenalytixAI to support prospective revenue-generating contract research, clinical diagnostic and clinical trial services that are part of the Company's core business model with KidneyIntelX and other products under development.”

Reference:

http://www.akesogen.com/category/news/